Department of Hematology, Lanzhou University Second Hospital, Lanzhou, 730030, Gansu, China.
Ann Hematol. 2024 Aug;103(8):2671-2680. doi: 10.1007/s00277-023-05560-4. Epub 2023 Nov 27.
Chemokine ligand 13 (CXCL13) and its chemokine receptor 5 (CXCR5) both play significant roles in the tumor microenvironment (TME). CXCL13 in cerebrospinal fluid (CSF) has recently been found to have significant diagnostic and prognostic value in primary and secondary central nervous system (CNS) diffuse large B-cell lymphoma (DLBCL), and the CXCL13-CXCR5 axis has been shown to play an important chemotactic role in the TME of CNS-DLBCL. In this review, we first describe the clinical value of CXCL13 in CSF as a prognostic and diagnostic biomarker for CNS-DLBCL. In addition, this review also discusses the specific mechanisms associated with the CXCL13-CXCR5 axis in tumor immunity of primary diffuse large B cell lymphoma of the central nervous system (PCNS-DLBCL) by reviewing the specific mechanisms of this axis in the immune microenvironment of DLBCL and CNS inflammation, as well as the prospects for the use of CXCL13-CXCR5 axis in immunotherapy in PCNS-DLBCL.
趋化因子配体 13(CXCL13)及其趋化因子受体 5(CXCR5)在肿瘤微环境(TME)中都发挥着重要作用。最近发现脑脊液(CSF)中的 CXCL13 在原发性和继发性中枢神经系统(CNS)弥漫性大 B 细胞淋巴瘤(DLBCL)中具有重要的诊断和预后价值,CXCL13-CXCR5 轴在 CNS-DLBCL 的 TME 中发挥着重要的趋化作用。在这篇综述中,我们首先描述了 CSF 中 CXCL13 作为 CNS-DLBCL 预后和诊断生物标志物的临床价值。此外,通过综述该轴在 DLBCL 免疫微环境和 CNS 炎症中的特定机制,以及 CXCL13-CXCR5 轴在 PCNS-DLBCL 免疫治疗中的应用前景,本文还讨论了 CXCL13-CXCR5 轴在 CNS 原发性弥漫性大 B 细胞淋巴瘤(PCNS-DLBCL)肿瘤免疫中的具体机制。